Ratan Capital Management LP Acquires Shares of 20,000 Solventum Corporation $SOLV

Ratan Capital Management LP acquired a new stake in shares of Solventum Corporation (NYSE:SOLV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,000 shares of the company’s stock, valued at approximately $1,543,000. Solventum makes up approximately 0.5% of Ratan Capital Management LP’s portfolio, making the stock its 29th biggest position.

A number of other institutional investors also recently modified their holdings of SOLV. Independent Franchise Partners LLP lifted its holdings in shares of Solventum by 19.0% in the 4th quarter. Independent Franchise Partners LLP now owns 15,355,691 shares of the company’s stock worth $1,216,785,000 after purchasing an additional 2,456,451 shares in the last quarter. Diamond Hill Capital Management LLC Investment Advisor acquired a new stake in Solventum in the 2nd quarter valued at $150,066,000. Norges Bank bought a new stake in Solventum during the 4th quarter valued at $147,467,000. Diamond Hill Capital Management Inc. increased its stake in Solventum by 152.2% during the 4th quarter. Diamond Hill Capital Management Inc. now owns 2,109,027 shares of the company’s stock valued at $167,119,000 after purchasing an additional 1,272,921 shares in the last quarter. Finally, Boston Partners raised its holdings in Solventum by 26.1% during the third quarter. Boston Partners now owns 4,630,300 shares of the company’s stock worth $338,006,000 after buying an additional 959,543 shares during the last quarter.

Solventum Trading Up 0.1%

NYSE SOLV opened at $91.02 on Friday. The firm has a market capitalization of $15.49 billion, a P/E ratio of 11.13, a PEG ratio of 1.17 and a beta of 0.60. The business has a fifty day simple moving average of $82.46 and a 200 day simple moving average of $75.55. Solventum Corporation has a 12 month low of $62.38 and a 12 month high of $92.71. The company has a current ratio of 1.02, a quick ratio of 0.74 and a debt-to-equity ratio of 1.00.

Solventum (NYSE:SOLV) last issued its quarterly earnings data on Wednesday, August 5th. The company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $1.91 by $0.64. Solventum had a return on equity of 25.09% and a net margin of 17.26%.The business had revenue of $2.21 billion for the quarter, compared to analysts’ expectations of $2.15 billion. During the same period last year, the business earned $1.69 EPS. The business’s revenue was up 2.2% on a year-over-year basis. Solventum has set its FY 2026 guidance at 7.100-7.200 EPS. On average, analysts predict that Solventum Corporation will post 7.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on SOLV shares. Piper Sandler raised their price objective on shares of Solventum from $92.00 to $105.00 and gave the company an “overweight” rating in a research note on Thursday, August 6th. UBS Group boosted their target price on shares of Solventum from $95.00 to $101.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen lowered shares of Solventum from a “buy” rating to a “hold” rating in a report on Saturday, August 22nd. Wells Fargo & Company dropped their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research report on Wednesday, May 6th. Finally, Mizuho set a $113.00 price target on Solventum in a research note on Thursday, August 6th. Eight research analysts have rated the stock with a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Solventum presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.64.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.